
    
      Eligible subjects will be entered into a 1-week observation period followed by a 1-week
      run-in period. Following completion of the run-in period, eligible subjects will be
      randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a
      1:1 ratio. Study drug will be administered once daily at bedtime. Symptom assessment
      questionnaires will be administered at baseline and at Day 28 and Day 57 visits.
    
  